OTR3 - Events & News

News and Events

Meet us at

Arab Health 2023
WVAC 2023
EWMA 2023
WSAVA Congress 2023

Last news

Apr, 2023 – Publication

Publication in the “Aesthetic Surgery Journal Open Forum” from the Oxford University Press concerning “a retrospective self-controlled study evaluating the Prophylactic Effects of our Medical Device Cacipliq 20 on Postsurgical scars.”

Dec, 2022 – Clinical

OTR3 announces first patient enrollment in its pivotal study “MATRISCAR”, a double blind placebo-controlled study aimed at demonstrating the effects of CACIPLIQ20 on Post-surgical Scars

Mar 25, 2022 – Clinical

OTR3 announces first patient enrolled in a Phase I study of OTR4132-MD in Acute Ischemic Stroke (AIS).

Feb 10, 2022 – Clinical

OTR3 announces first patient enrolled in a post market clinical follow up on Cacipliq 20®..

Nov 9, 2021 – Clinical

OTR3 starts a post market clinical follow up on Cacipliq 20®.

Oct 8, 2021 – Clinical

OTR3 receives approval from ANSM to start new clinical trial with the application of a RGTA® product in ischemic stroke.

Aug 25, 2021 – Financial

OTR3 receives a state guaranteed loan amounting to € 0.5 m.

Jun 29, 2021 – Corporate

OTR3 appoints new management teams as the company planned to launch a second generation of RGTA® products.

Organes Tissus Regeneration Reparation Remplacement

Legal Notices and General Conditions of Use

ADDRESS

4, rue Française
75001 Paris, France

CONTACT

+33 (0)1 83 64 23 00